Year in Review

Year in review: 2018

IU Ventures launched the Indiana Philanthropic Venture Fund in March of 2018 to help achieve one of Indiana University’s Bicentennial Priorities: Building a Prosperous and Innovative Indiana.

The fund was established as a followup to the success of the Innovate Indiana Fund, which deployed $10 million into fifteen IU startup companies since its establishment in 2010.

The Philanthropic Venture Fund has $15 million to invest in companies based on IU technology, or companies with IU alumni as founders or members of the C-suite, with the goal of raising another $35 million from alumni and supporters of the university.

For more information about our portfolio companies, to inquire about funding, or if you are interested in donating to the fund, please contact us.

Our work, in numbers

106opportunities reviewed

17investment committee proposals

$2.9Minvested in 9 companies

$16.75Mraised by portfolio companies with our fund

Future funding and support

As we look forward to 2019, we plan to focus our efforts on:

Fundraising for our companies and our fund
Creating relationships with IU innovators and entrepreneurs
Expanding our existing portfolio to include leadership and sector diversity

Nine portfolio companies

Care Revolution

Care Revolution is based on the OPTIMISTIC clinical care model of reducing hospital transfers and increasing the quality of care to nursing homes across the country.

Explore Care Revolution

Diagnotes

Diagnotes is a HIPPAA-compliant and secure text, voice, and video platform for providers and their patients. A complete mobile clinical communication system integrates with any EHR system and gives real-time access to call schedules, with the ability to document every discussion.

Explore Diagnotes

Doxly

Doxly is a secure transaction management platform that centralizes checklists and reporting; tracks documents, tasks, and versions; and automates the entire signature management process.

Explore Doxly

ENCAMP

ENCAMP is a fast, simple, and accurate environmental reporting platform.

Explore ENCAMP

NERx

NERx focuses on the discovery and development of targeted therapeutics for cancer, specific to the Nucleotide Excision Repair (NER) pathway.

Explore NERx

Scioto Biosciences

Scioto is developing a microbiome-activated bacterial therapeutics platform, with the goal of successfully delivering and sustaining live therapeutic bacteria in the human gut to improve the microbiome—a major hurdle with conventional microbiome therapy to date.

Explore Scioto Biosciences